The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols.
Patient-reported outcomes (PROs) provide the patient's perspective of the impact of treatment. Evidence suggests that PRO content of randomised controlled trials (RCTs) protocols is generally sub-optimal. This study aimed to describe and evaluate the PRO-specific content of ovarian cancer RCT protocols.



Published, phase III, ovarian cancer RCTs with PRO endpoints were identified following a systematic search of Medline and Cochrane databases (Jan 2000 to Feb 2016). Corresponding RCT protocols were downloaded (if published) or obtained by contacting authors. Two investigators independently assessed adherence of PRO-specific content of included protocols to a checklist of 58 recommended PRO protocol items currently being developed by the International Society for Quality of Life Research. Discrepancies were resolved with a third investigator.



Of 41 eligible trials identified, 26 protocols were assessed (developed 1995-2010). We were unable to obtain the remaining 15 protocols. Protocols addressed a mean of 28 % PRO checklist items (range 8-66 %). Fifteen (58 % of assessed protocols) provided a rationale for PRO assessment, 8 (31 %) described a PRO objective, 24 (92 %) included a PRO assessment schedule, but only 6 (23 %) justified timing of PRO assessments. Twelve protocols (46 %) provided staff data collection instructions, 4 (15 %) included plans for monitoring PRO compliance, and 16 (62 %) included a PRO analysis plan.



On average, protocols addressed less than one-third of PRO protocol checklist items. In some cases, key guidance regarding PRO administration was lacking, which may lead to inconsistent and sub-optimal PRO methodology. Efforts are needed to improve PRO protocol content in cancer trials.
Central Clinical School, Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia. Rebecca.mercieca@sydney.edu.au.|Quality of Life Office, Psycho-oncology Co-operative Research Group, School of Psychology, University of Sydney, Level 6 North, Chris O'Brien Lifehouse C39Z, Sydney, NSW, 2006, Australia. Rebecca.mercieca@sydney.edu.au.
Rebecca
0000-0003-3708-9099
R
Mercieca-Bebber
NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, 2006, Australia.|Australian New Zealand Gynecological Oncology Group (ANZGOG), Camperdown, NSW, 2050, Australia.
Michael
M
Friedlander
NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, 2006, Australia.|Australian New Zealand Gynecological Oncology Group (ANZGOG), Camperdown, NSW, 2050, Australia.
Peey-Sei
PS
Kok
Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Melanie
M
Calvert
Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Derek
D
Kyte
NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, 2006, Australia.
Martin
M
Stockler
Central Clinical School, Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia.|Quality of Life Office, Psycho-oncology Co-operative Research Group, School of Psychology, University of Sydney, Level 6 North, Chris O'Brien Lifehouse C39Z, Sydney, NSW, 2006, Australia.|Australian New Zealand Gynecological Oncology Group (ANZGOG), Camperdown, NSW, 2050, Australia.
Madeleine T
MT
King
D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms; D000071066:Patient Reported Outcome Measures; D011788:Quality of Life / Q000523:psychology*; D016032:Randomized Controlled Trials as Topic / Q000379:methods*
Clinical trials as topic; Guideline adherence; Ovarian cancer; Patient-reported outcomes; Protocol checklist; Quality of life